Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06676072 · ClinicalTrials.gov registry record · NA

A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:

A NA study of Atrial Fibrillation (AF) and Atrial Arrhythmia, sponsored by Abbott Medical Devices.

Active
Registry status
NA
Development phase
188
Enrollment target
20
Study locations

NCT06676072 is a NA study of Atrial Fibrillation (AF) and Atrial Arrhythmia that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 188 participants, below the 709-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06676072, a NA study of Atrial Fibrillation (AF) and Atrial Arrhythmia, is active but no longer recruiting, sponsored by Abbott Medical Devices.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
188 participants
Enrollment target
20
Study locations

Study Summary

The objective of this clinical study is to demonstrate that ablation with the TactiFlex SE Ablation catheter, in conjunction with a compatible pulsed field ablation (PFA) and/or radio frequency (RF) generator, is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxysmal atrial fibrillation (PAF).

Conditions Studied

Atrial Fibrillation (AF) Atrial Arrhythmia Paroxysmal AF Drug Refractory Paroxysmal Atrial Fibrillation

Interventions

  • DEVICE PFA Ablation catheter

Study Locations (20)

Florida

  • HCA Florida Mercy Hospital - Miami
  • AdventHealth Orlando - Orlando
  • Tallahassee Research Institute - Tallahassee

Michigan

  • University of Michigan Medical Center - Ann Arbor
  • Henry Ford Providence Southfield Hospital - Southfield

New York

  • NYU Langone Health - New York
  • New York Presbyterian Hospital/Cornell University - New York

Arizona

  • HonorHealth - Scottsdale

Arkansas

  • Arkansas Heart Hospital - Little Rock

California

  • Stanford University Medical Center - Stanford

Colorado

  • South Denver Cardiology Associates PC - Littleton

Georgia

  • Piedmont Athens Regional Medical Center - Athens

Trial Details

FieldValue
Enrollment Target 188 participants
Start Date 2024-11-22
Est. Completion 2026-04-30
Phase NA

Sponsor

Abbott Medical Devices

261 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06676072

The ClinicalTrials.gov registry entry for NCT06676072 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 709-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (73% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 1 intervention - of which PFA Ablation catheter is the first listed.

NCT06676072 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT06676072 about?

NCT06676072 is a clinical study titled "A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:". The objective of this clinical study is to demonstrate that ablation with the TactiFlex SE Ablation catheter, in conjunction with a compatible pulsed field ablation (PFA) and/or radio frequency (RF) generator, is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxys...

What is the current status of trial NCT06676072?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 188 participants. The study started on 2024-11-22. Estimated completion is 2026-04-30.

What conditions does trial NCT06676072 study?

This clinical trial studies the following conditions: Atrial Fibrillation (AF), Atrial Arrhythmia, Paroxysmal AF, Drug Refractory Paroxysmal Atrial Fibrillation.

What interventions are being tested in trial NCT06676072?

The interventions under investigation include: PFA Ablation catheter (DEVICE).

Who is sponsoring clinical trial NCT06676072?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06676072 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation (AF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation (AF)

All registered trials for this condition

Atrial Arrhythmia

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.